Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primary vaccination with homologous adeno-vectored ChAdOx1 nCoV-19 vaccine (ChAd) or heterologous ChAd/BNT162b2 mRNA vaccine (BNT), anti-spike-IgG and SARS-CoV-2 VOC-neutralizing antibody responses were measured in 354 healthcare workers (HCW) at 2 weeks, 3 months, 5 months and 6 months after the second vaccine dose. T-cell responses were investigated using a whole blood interferon gamma (IFN-γ) release assay 2 weeks and 3 months post second vaccine dose. Two hundred and ten HCW immunized with homologous BNT were enrolled for comparison of antibody responses. In study participants naïve to SARS-CoV-2 prior to vaccination, heterologous ChAd/BNT resulted in 6-fold higher peak anti-spike IgG antibody titers compared to homologous ChAd vaccination. The half-life of antibody titers was 3.1 months (95% CI 2.8–3.6) following homologous ChAd vaccination and 1.9 months (95% CI 1.7–2.1) after heterologous vaccination, reducing the GMT difference between the groups to 3-fold 6 months post vaccination. Peak T-cell responses were stronger in ChAd/BNT vaccinees, but no significant difference was observed 3 months post vaccination. SARS-CoV-2 infection prior to vaccination resulted in substantially higher peak GMTs and IFN-γ levels and enhanced SARS-CoV-2 specific antibody and T cell responses over time. Heterologous primary SARS-CoV-2 immunization with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.

[1]  D. von Laer,et al.  SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons , 2022, The New England journal of medicine.

[2]  F. Kirchhoff,et al.  Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity , 2021, medRxiv.

[3]  P. Nilsson,et al.  Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. , 2021, JAMA.

[4]  V. Libri,et al.  Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.

[5]  T. Leino,et al.  Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021 , 2021, Vaccine.

[6]  C. Fjell,et al.  Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada , 2021, medRxiv.

[7]  A. Nordström,et al.  Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study , 2021, The Lancet Regional Health - Europe.

[8]  Y. Tyan,et al.  The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2 , 2021, Vaccines.

[9]  P. Dönnes,et al.  An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses , 2021, PloS one.

[10]  J. Castilla,et al.  Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  P. Dönnes,et al.  Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19 , 2021, Journal of internal medicine.

[12]  A. Vallée,et al.  An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines , 2021, Journal of clinical medicine.

[13]  F. Huang,et al.  To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination , 2021, Expert review of vaccines.

[14]  J. Izopet,et al.  Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2 , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  F. Cosset,et al.  Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination , 2021, Nature.

[16]  V. Libri,et al.  Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[17]  M. Zeier,et al.  Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers , 2021, Vaccines.

[18]  C. von Kalle,et al.  Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[19]  B. Gärtner,et al.  Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination , 2021, Nature Medicine.

[20]  J. Münch,et al.  Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.

[21]  K. Überla,et al.  Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 , 2021, The Lancet Infectious Diseases.

[22]  S. Ladhani,et al.  Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  A. Borobia,et al.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[24]  D. Stuart,et al.  Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status , 2021, Clinical Microbiology and Infection.

[25]  M. Snape,et al.  Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data , 2021, The Lancet.

[26]  S. Hober,et al.  Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 , 2021, EBioMedicine.

[27]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[28]  Heterologous primary and booster COVID-19 vaccination , 2021 .

[29]  A. Nordström,et al.  Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study , 2021, SSRN Electronic Journal.

[30]  H. Tegel,et al.  SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden , 2020, Nature Communications.

[31]  H. Ljunggren,et al.  Expansion of SARS-CoV-2–Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients , 2020, The Journal of Immunology.

[32]  S. Kochanek,et al.  The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.